- 500-99-2Phenol, 3,5-dimethoxy-
- 500995-45-9Hydrazine,[4-(hydrazinomethyl)phenyl]- (9CI)
- 501-00-8Benzeneacetonitrile,3-fluoro-
- 501008-41-9Benzeneacetonitrile,5-fluoro-2-methoxy-
- 501014-42-24H-1,3,6,2-Dioxazaborocine,2-[(1Z)-1,2-diphenylethenyl]tetrahydro-
- 501015-16-3Benzenepropanoic acid, 3-bromo-b-[[(1,1-dimethylethoxy)carbonyl]amino]-,(bR)-
- 501015-30-1Benzenepropanoicacid, b-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-methoxy-,(bS)-
- 501019-88-1Oxirane, 2-methyl-,polymer with oxirane, mono-C8-10-alkyl ethers, ethers with 1,2-decanediol (1:1)
- 50-10-2Oxyphenonium bromide
- 501088-17-1Methyl2-azido-2-deoxy-3-O-(phenylmethyl)-alpha-D-glucopyranoside6-benzoate
Hot Products
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
- 7631-86-9Silicon dioxide
- 302-79-4Tretinoin
- 77-92-9Citric acid
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Evipal sodium |
EINECS | N/A |
| CAS No. | 50-09-9 | Density | N/A |
| PSA | N/A | LogP | N/A |
| Solubility | N/A | Melting Point |
N/A |
| Formula | C12H15N2O3•Na | Boiling Point | 368.8°C at 760 mmHg |
| Molecular Weight | 258.252 | Flash Point | 176.8°C |
| Transport Information | N/A | Appearance | N/A |
| Safety | Poison by intraperitoneal, parenteral, and intravenous routes. Moderately toxic by ingestion and subcutaneous routes. Used intravenously as a general anesthetic. When heated to decomposition it emits toxic fumes of NOx and Na2O. See also EVIPAL and BARBITURATES. | Risk Codes | N/A |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
N/A |
Evipal sodium Chemical Properties
IUPAC Name: Sodium 5-cyclohexen-1-yl-1,5-dimethylpyrimidin-3-ide-2,4,6-trione
Synonyms of Evipal sodium (CAS NO.50-09-9) : 1,5-Dimethyl-5-cyclohexenyl-1'-barbituric acid, sodium salt ; 5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione monosodium salt ; Cyclohexenylmethyl-N-methyl barbituric acid sodium salt ; Cyclonal sodium ; Hexenal sodium ; Methexenyl sodium ; Sodium 5-(1-cyclohexen-1-yl)-1,5-dimethylbarbiturate ; Sodium methylhexabitol ; Sombulex 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, sodium salt ; Barbituric acid, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, sodium salt
CAS NO:50-09-9
Molecular Formula:C12H15N2NaO3
Molecular Weight :258.2568
Molecular Structure :.png)
EINECS: 200-009-1
Flash Point: 176.8 °C
Enthalpy of Vaporization: 71.22 kJ/mol
Boiling Point: 368.8 °C at 760 mmHg
Vapour Pressure: 6.12E-07 mmHg at 25°C
Evipal sodium Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LDLo | intravenous | 85mg/kg (85mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC | Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 125, 1937. |
| dog | LDLo | subcutaneous | 107mg/kg (107mg/kg) | BEHAVIORAL: SLEEP | Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 323, 1937. |
| frog | LDLo | parenteral | 30mg/kg (30mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 50, Pg. 347, 1934. | |
| guinea pig | LDLo | intraperitoneal | 100mg/kg (100mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA BEHAVIORAL: COMA | Journal of Pharmacology and Experimental Therapeutics. Vol. 50, Pg. 347, 1934. |
| mouse | LD50 | intraperitoneal | 240mg/kg (240mg/kg) | Acta Biologica et Medica Germanica. Vol. 6, Pg. 407, 1961. | |
| mouse | LD50 | intravenous | 165mg/kg (165mg/kg) | Toxicology and Applied Pharmacology. Vol. 23, Pg. 537, 1972. | |
| mouse | LD50 | oral | 1325mg/kg (1325mg/kg) | Toxicology and Applied Pharmacology. Vol. 27, Pg. 70, 1974. | |
| mouse | LD50 | subcutaneous | 410mg/kg (410mg/kg) | Toxicology and Applied Pharmacology. Vol. 27, Pg. 70, 1974. | |
| rabbit | LD50 | intravenous | 72mg/kg (72mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 87, Pg. 265, 1946. | |
| rabbit | LDLo | intraperitoneal | 150mg/kg (150mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 54, Pg. 77, 1935. | |
| rat | LCLo | inhalation | 2000ppm/4H (2000ppm) | AMA Archives of Industrial Hygiene and Occupational Medicine. Vol. 10, Pg. 61, 1954. | |
| rat | LD50 | intraperitoneal | 375mg/kg (375mg/kg) | Journal of Pharmacy and Pharmacology. Vol. 21, Pg. 109, 1969. | |
| rat | LD50 | oral | 1gm/kg (1000mg/kg) | Archives of Toxicology. Vol. 54, Pg. 275, 1983. | |
| rat | LDLo | subcutaneous | 363mg/kg (363mg/kg) | BEHAVIORAL: SLEEP | Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 323, 1937. |
Evipal sodium Safety Profile
Poison by intraperitoneal, parenteral, and intravenous routes. Moderately toxic by ingestion and subcutaneous routes. Used intravenously as a general anesthetic. When Evipal sodium (CAS NO.50-09-9) is heated to decomposition ,it emits toxic fumes of NOx and Na2O. See also EVIPAL and BARBITURATES.
RIDADR: 3249
HazardClass: 6.1(b)
PackingGroup: III
What can I do for you?
Get Best Price
